drug_type
RELEVANT_DRUG
intervention_type
Vaccine (mRNA boost)
drug_description
KRAS-targeted mRNA vaccine used as a boost to expand KRAS-mutant–specific T cells and support infused cells.
nci_thesaurus_concept_id
C165515
nci_thesaurus_preferred_term
Neoantigen-based Therapeutic Cancer Vaccine GRT-R904
nci_thesaurus_definition
A cancer boosting vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-based therapeutic cancer vaccine GRT-R904, which is administered after the initial administration of the priming vaccine GRT-C903, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.
drug_category
mRNA VACCINE
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
An mRNA cancer vaccine encoding shared KRAS neoantigens. After administration (as a boost following a priming vaccine), antigen-presenting cells translate the mRNA and present the neoantigen peptides on MHC I/II, expanding KRAS-mutant–specific CD8+ and CD4+ T cells and enhancing cytotoxic killing of tumor cells expressing KRAS mutations, including support of infused KRAS-specific TCR T cells.
drug_name
GRT-R904
nct_id_drug_ref
NCT06253520